Your browser doesn't support javascript.
loading
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.
Fissolo, Nicolás; Benkert, Pascal; Sastre-Garriga, Jaume; Mongay-Ochoa, Neus; Vilaseca-Jolonch, Andreu; Llufriu, Sara; Blanco, Yolanda; Hegen, Harald; Berek, Klaus; Perez-Miralles, Francisco; Rejdak, Konrad; Villar, Luisa M; Monreal, Enric; Alvarez-Lafuente, Roberto; Soylu, Onder K; Abdelhak, Ahmed; Bachhuber, Franziska; Tumani, Hayrettin; Martínez-Yélamos, Sergio; Sánchez-López, Antonio J; García-Merino, Antonio; Gutiérrez, Lucía; Castillo-Trivino, Tamara; Lycke, Jan; Rosenstein, Igal; Furlan, Roberto; Filippi, Massimo; Téllez, Nieves; Ramió-Torrentà, Lluís; Lünemann, Jan D; Wiendl, Heinz; Eichau, Sara; Khalil, Michael; Kuhle, Jens; Montalban, Xavier; Comabella, Manuel.
Afiliación
  • Fissolo N; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Benkert P; Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
  • Sastre-Garriga J; Department of Neurology, University Hospital and University of Basel, Basel, Switzerland.
  • Mongay-Ochoa N; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Vilaseca-Jolonch A; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Llufriu S; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Blanco Y; Center of Neuroimmunology, Service of Neurology, Hospital Clinic and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
  • Hegen H; Center of Neuroimmunology, Service of Neurology, Hospital Clinic and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
  • Berek K; Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.
  • Perez-Miralles F; Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.
  • Rejdak K; Neuroimmunology Unit, València University and Polytechnic Hospital La Fe, Valencia, Spain.
  • Villar LM; Department of Neurology, Medical University of Lublin, Lublin, Poland.
  • Monreal E; Departments of Neurology and Immunology, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal deInvestigacion Sanitaria (IRYCIS), Madrid, Spain.
  • Alvarez-Lafuente R; Department of Neurology, Hospital Universitario Ramón y Cajal, REEM, IRYCIS, Universidad de Alcalá, Madrid, Spain.
  • Soylu OK; Environmental Factors in Degenerative Diseases Research Group, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico SanCarlos (IdISSC), Madrid, Spain.
  • Abdelhak A; Department of Neurology, Ulm University, Ulm, Germany.
  • Bachhuber F; Department of Neurology, Ulm University, Ulm, Germany.
  • Tumani H; Department of Neurology, Division of Neuroinflammation and Glial Biology, University of California San Francisco, San Francisco, California, USA.
  • Martínez-Yélamos S; Department of Neurology, Ulm University, Ulm, Germany.
  • Sánchez-López AJ; Department of Neurology, Ulm University, Ulm, Germany.
  • García-Merino A; Neurology Department, Multiple Sclerosis Unit, Hospital Universitari deBellvitge-IDIBELL, Universitat de Barcelona, Barcelona, Spain.
  • Gutiérrez L; Neuroimmunology Unit, Puerta de Hierro-Segovia de Arana Health Research Institute, Madrid, Spain.
  • Castillo-Trivino T; Biobank, Puerta de Hierro-Segovia de Arana Health Research Institute, Madrid, Spain.
  • Lycke J; Neuroimmunology Unit, Puerta de Hierro-Segovia de Arana Health Research Institute, Madrid, Spain.
  • Rosenstein I; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Furlan R; Neurology Department, Donostia University Hospital, San Sebastian, Spain.
  • Filippi M; Department of Clinical Neuroscience, Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Téllez N; Department of Clinical Neuroscience, Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Ramió-Torrentà L; Clinical Neuroimmunology Unit, Division of Neuroscience, Institute of Experimental Neurology, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Lünemann JD; Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milano, Italy.
  • Wiendl H; Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Eichau S; Neurophysiology Service, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Khalil M; Neurorehabilitation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Kuhle J; Università Vita Salute San Raffaele, Milano, Italy.
  • Montalban X; Neurology Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
  • Comabella M; Girona Neuroimmunology and Multiple Sclerosis Unit, Neurology Department,Hospital Universitari Dr. Josep Trueta and Hospital Santa Caterina.Neurodegeneration and Neuroinflammation research group (IDIBGI). Department of Medical Sciences, University of Girona, Girona, Spain.
J Neurol Neurosurg Psychiatry ; 95(5): 410-418, 2024 Apr 12.
Article en En | MEDLINE | ID: mdl-37940409
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Personas con Discapacidad / Esclerosis Múltiple Crónica Progresiva / Esclerosis Múltiple Límite: Female / Humans / Male / Middle aged Idioma: En Revista: J Neurol Neurosurg Psychiatry Año: 2024 Tipo del documento: Article País de afiliación: España
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Personas con Discapacidad / Esclerosis Múltiple Crónica Progresiva / Esclerosis Múltiple Límite: Female / Humans / Male / Middle aged Idioma: En Revista: J Neurol Neurosurg Psychiatry Año: 2024 Tipo del documento: Article País de afiliación: España